Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010

Mycoses

Volumn 58, Issue 8, 2015, Pages 498-505

  Alp, Sehnaz ^a   Arikan Akdagli, Sevtap ^a   Gulmez, Dolunay ^a   Ascioglu, Sibel ^a   Uzun, Omrum ^a   Akova, Murat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Candida albicans; Candidaemia; Epidemiology; Non albicans Candida

Indexed keywords

ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; DISEASE PREDISPOSITION; FEMALE; FUNGUS ISOLATION; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATHOGENESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPECIES DISTRIBUTION; TERTIARY CARE CENTER; UNIVERSITY HOSPITAL; URINARY CATHETER; CANDIDA; CLASSIFICATION; COMPLICATION; CROSS INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TERTIARY HEALTH CARE; TIME FACTOR; TURKEY;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

ADULT; AGED; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CANDIDEMIA; CROSS INFECTION; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY HEALTHCARE; TIME FACTORS; TURKEY;

EID: 84937730300     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12349     Document Type: Article

References (83)

1. Chang A, Neofytos D, Horn D. Candidaemia in the 21st century. Future Microbiol 2008; 3: 463-72.
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
3. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007; 45: 321-46.
4. Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag 2014; 10: 95-105.
5. Sievert DM, Ricks P, Edwards JR et al.; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34: 1-14.
6. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
7. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003; 22: 686-91.
8. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with haematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103-10.
9. Bouza E, Perez-Molina J, Munoz P; Report of ESGNI-001 and ESGNI-002 studies. Bloodstream infections in Europe. Clin Microbiol Infect 1999; 5(Suppl 2): 2S1-12.
10. Alonso-Valle H, Acha O, Garcia-Palomo JD, Fariñas-Alvarez C, Fernández-Mazarrasa C, Fariñas MC. Candidaemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 2003; 22: 254-7.
11. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidaemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
12. Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidaemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43.
13. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidaemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
14. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
15. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidaemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703.
16. Tortorano AM, Peman J, Bernhardt H et al.; ECMM Working Group on Candidaemia. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-22.
17. Pfaller MA, Diekema DJ, Gibbs DL et al.; Global Antifungal Surveillance Group. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5 year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-77.
18. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY antimicrobial surveillance program (2008-2009). J Clin Microbiol 2011; 49: 396-9.
19. Safdar A, Armstrong D, Cross EW, Perlin DS. Prospective epidemiologic analysis of triazole-resistant nosocomial Candida glabrata isolated from patients at a comprehensive cancer center. Int J Infect Dis 2002; 6: 198-201.
20. Swinne D, Watelle M, Van der Flaes M, Nolard N. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-C. albicans bloodstream yeast isolates (CANARI study). Mycoses 2004; 47: 177-83.
21. Diekema DJ, Messer SA, Brueggemann AB et al. Epidemiology of candidaemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40: 1298-302.
22. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50: 1199-203.
23. Orozco AS, Higginbotham LM, Hitchcock CA et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998; 42: 2645-9.
24. Krcmery V Jr, Mrazova M, Kunova A et al. Nosocomial candidaemias due to species other than Candida albicans in cancer patients. Aetiology, risk factors, and outcome of 45 episodes within 10 years in a single cancer institution. Support Care Cancer 1999; 7: 428-31.
25. Kaiyar SK, Edlind TD. Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei. Med Mycol 2001; 39: 109-16.
26. Larone DH. Medically Important Fungi: A Guide to Identification, 3rd ed. Washington D.C.: ASM Press., 1995.
27. Arendrup MC, Bruun B, Christensen JJ et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011; 49: 325-34.
28. Arendrup MC, Dzajic E, Jensen RH et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013; 19: E343-53.
29. Poikonen E, Lyytikäinen O, Anttila VJ et al. Secular trend in candidaemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 2010; 10: 312.
30. Ericsson J, Chryssanthou E, Klingspor L et al. Candiaemia in Sweden: a nationwide prospective observational survey. Clin Microbiol Infect Dis 2013; 19: E218-21.
31. Poikonen E, Lyytikäinen O, Anttila VJ, Ruutu P. Candidaemia in Finland, 1995-1999. Emerg Infect Dis 2003; 9: 985-90.
32. Marchetti O, Bille J, Fluckiger U et al.; Fungal Infection Network of Switzerland. Epidemiology of candidaemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-20.
33. Kibbler CC, Seaton S, Barnes RA et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 2003; 54: 18-24.
34. vonBorg- Zepelin M, Kunz L, Rüchel R, Reichard U, Weig M, Gross U. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother 2007; 60: 424-8.
35. Cisterna R, Ezpeleta G, Tellaria O; Spanish Candidaemia Surveillance Group. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospital in Spain. J Clin Microbiol 2010; 48: 4200-6.
36. Pemán J, Cantón E, Quindós G et al.; FUNGEMYCA Study Group. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother 2012; 67: 1181-7.
37. Ortega M, Marco F, Soriano A et al. Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J Hosp Infect 2011; 77: 157-61.
38. Marco F, Danés C, Almela M et al. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida spp. bloodstream isolates. Results from a six-year study (1996-2001). Diagn Microbiol Infect Dis 2003; 46: 259-64.
39. Almirante B, Rodriguez D, Park BJ, et al.; Barcelona Candidaemia Project Study Group. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-35.
40. Montagna MT, Caggiano G, Lovero G et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection 2013; 41: 645-53.
41. Tortorano AM, Prigitano A, Lazzarini C et al. A 1-year prospective survey of candidaemia in Italy and changing epidemiology over one decade. Infection 2013; 41: 655-62.
42. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidaemia in a tertiary care hospital in Italy. PLoS ONE 2011; 6: e24198.
43. Córdoba S, Vivot W, Bosco-Borgeat ME et al.; Red Nacional De Laboratorios De Micologia. Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. Rev Argent Microbiol 2011; 43: 176-85.
44. Nucci M, Queiroz-Telles F, Alvarado-Matute T et al.; Latin American Invasive Mycosis Network. Epidemiology of candidaemia in Latin America: a laboratory-based survey. PLoS ONE 2013; 8: e59373.
45. Aquino VR, Lunardi LW, Goldani LZ, Barth AL. Prevalence, susceptibility profile for fluconazole and risk factors for candidaemia in a tertiary care hospital in southern Brazil. Braz J Infect Dis 2005; 9: 411-8.
46. Rodero L, Davel G, Soria M et al. Multicenter study of fungemia due to yeasts in Argentina. Rev Argent Microbiol 2005; 37: 189-95.
47. ®) registry, 2004-2008. Diagn Microbiol Infect Dis 2012; 74: 323-31.
48. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-27.
49. Colombo AL, Nucci M, Park BJ et al.; Brazilian Network Candidaemia Study. Epidemiology of candidaemia in Brazil: a nationwide sentinel surveillance of candidaemia in eleven medical centers. J Clin Microbiol 2006; 44: 2816-23.
50. Hung CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Nosocomial candidaemia in a university hospital in Taiwan. J Formos Med Assoc 1996; 95: 19-28.
51. Cheng YR, Lin LC, Young TG, Liu CE, Chen CH, Tsay RW. Risk factors for candidaemia-related mortality at a medical center in central Taiwan. J Microbiol Immunol Infect 2006; 39: 155-61.
52. Foongladda S, Sakulmaiwatana P, Petlum P, Vanprapar N. Candida species, genotypes and antifungal susceptibility of Candida isolates from blood samples of patients at the largest tertiary care hospital in Thailand during 1999-2002. J Med Assoc Thai 2004; 87: 92-9.
53. Al-Jasser AM, Elkhizzi NA. Distribution of Candida species among bloodstream isolates. Saudi Med J 2004; 25: 566-9.
54. Ellis M, Hedstrom U, Jumaa P, Bener A. Epidemiology, presentation, management and outcome of candidaemia in a tertiary care teaching hospital in the United Arab Emirates, 1995-2001. Med Mycol 2003; 41: 521-8.
55. Safdar A, Chaturvedi V, Cross EW et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 2001; 45: 2129-33.
56. Antoniadou A, Torres HA, Lewis RE et al. Candidaemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003; 82: 309-21.
57. Viscoli C, Girmenia C, Marinus A et al. Candidaemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-9.
58. Aydin F, Bayramoglu G, Guler NC, Kaklikkaya N, Tosun I. Bloodstream yeast infections in a university hospital in Northeast Turkey: a 4-year survey. Med Mycol 2011; 49: 316-9.
59. Bakir M, Cerikcioglu N, Barton R, Yagci A. Epidemiology of candidaemia in a Turkish tertiary care hospital. APMIS 2006; 114: 601-10.
60. Kazak E, Akin H, Ener B et al. An investigation of Candida species isolated from blood cultures during 17 years in a university hospital. Mycoses 2014; 57: 623-9.
61. Yenigün Koçak B, Kuloglu F, Dogan Çelik A, Akata F. Evaluation of epidemiological characteristics and risk factors of candidaemia in adult patients in a tertiary-care hospital. Mikrobiyol Bul 2011; 45: 489-503.
62. Yapar N, Pullukcu H, Avkan-Oguz V et al. Evaluation of species distribution and risk factors of candidaemia: a multicenter case-control study. Med Mycol 2011; 49: 26-31.
63. Yapar N, Uysal U, Yucesoy M, Cakir N, Yuce A. Nosocomial bloodstream infections associated with Candida species in a Turkish University Hospital. Mycoses 2006; 49: 134-8.
64. Erdem I, Oguzoglu N, Ozturk Engin D et al. Incidence, etiology and risk factors associated with mortality of nosocomial candidaemia in a tertiary care hospital in Istanbul, Turkey. Med Princ Pract 2010; 19: 463-7.
65. Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41: 1455-60.
66. Rueping MJ, Vehreschild JJ, Cornely OA. Invasive candidiasis and candidaemia: from current opinions to future perspectives. Expert Opin Investig Drugs 2009; 18: 735-48.
67. Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009; 52: 197-205.
68. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006; 20: 485-506.
69. Eubanks PJ, de Virgilio C, Klein S, Bongard F. Candida sepsis in surgical patients. Am J Surg 1993; 166: 617-9; discussion 619-620.
70. Giamarellou H. Nosocomial cardiac infections. J Hosp Infect 2002; 50: 91-105.
71. Nucci M, Pulcheri W, Spector N et al. Fungal infections in neutropenic patients. An 8-year prospective study. Rev Inst Med Trop Sao Paulo 1995; 37: 397-406.
72. Lin MY, Carmeli Y, Zumsteg J et al. Prior antimicrobial therapy and risk for hospital acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005; 49: 4555-60.
73. Playford GE, Marriott D, Nguyen Q et al. Candidaemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008; 36: 2034-9.
74. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008; 106: 523-9.
75. Chow JK, Golan Y, Ruthazer R et al. Factors associated with candidaemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008; 46: 1206-13.
76. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20: 115-25.
77. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847-9.
78. Lewis RE. Overview of the changing epidemiology of candidaemia. Curr Med Res Opin 2009; 25: 1732-40.
79. Clark TA, Slavinski SA, Morgan J et al. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol 2004; 42: 4468-72.
80. Girmenia C, Martino P, De BF et al. Rising incidence of Candida parapsilosis fungemia in patients with haematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996; 23: 506-14.
81. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11: 379-90.
82. Kontoyiannis DP, Vaziri I, Hanna HA et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001; 33: 1676-81.
83. Bodey GP, Mardani M, Hanna HA et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112: 380-5.